
Quarterly report 2023-Q1
added 05-11-2023
Satsuma Pharmaceuticals Net Debt 2011-2026 | STSA
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Satsuma Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -33.3 M | -17.8 M | -240 K | -1.56 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -240 K | -33.3 M | -13.2 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.97 | 6.43 % | $ 9.55 B | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-5.45 M | $ 5.12 | 11.55 % | $ 345 B | ||
|
Aligos Therapeutics
ALGS
|
-132 M | $ 7.66 | 3.23 % | $ 75.7 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
-604 M | $ 320.13 | -3.98 % | $ 41.9 B | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
457 M | $ 21.81 | 0.6 % | $ 1.02 B | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 4.67 | -1.37 % | $ 766 M | ||
|
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 102.12 | 2.66 % | $ 27.2 B | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 3.08 | -4.94 % | $ 5.07 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
-133 M | $ 1.35 | -12.9 % | $ 347 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.26 | 0.47 % | $ 456 M | ||
|
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B | ||
|
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 24.19 | -1.59 % | $ 3.08 B | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.61 | 8.05 % | $ 428 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
-163 M | - | - | $ 546 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Cidara Therapeutics
CDTX
|
-188 M | - | - | $ 1.41 B | ||
|
BioXcel Therapeutics
BTAI
|
56.3 M | $ 1.07 | 1.9 % | $ 13.1 M | ||
|
Cabaletta Bio
CABA
|
-76.6 M | $ 3.52 | 3.53 % | $ 354 M | ||
|
CymaBay Therapeutics
CBAY
|
-206 M | - | - | $ 3.45 B | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
ChromaDex Corporation
CDXC
|
-62 M | - | -0.88 % | $ 598 M |